104 related articles for article (PubMed ID: 19767656)
1. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: moving targets.
van Oers MH
Neth J Med; 2009 Sep; 67(8):309-10. PubMed ID: 19767656
[No Abstract] [Full Text] [Related]
2. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
3. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
Korolenko VO; Gershanovich ML; Tikhonova VV
Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
[No Abstract] [Full Text] [Related]
4. Interaction between statins and rituximab in non-Hodgkin's lymphoma.
Rabinowitz I
J Clin Oncol; 2008 Nov; 26(33):5486; author reply 5486. PubMed ID: 18936467
[No Abstract] [Full Text] [Related]
5. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.
Meyer zum Büschenfelde C; Feuerstacke Y; Götze KS; Scholze K; Peschel C
Cancer Res; 2008 Jul; 68(13):5414-22. PubMed ID: 18593944
[TBL] [Abstract][Full Text] [Related]
6. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
Akhtar S; Maghfoor I
J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496
[No Abstract] [Full Text] [Related]
7. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.
Rothe A; Schulz H; Elter T; Engert A; Reiser M
Haematologica; 2004 Jul; 89(7):875-6. PubMed ID: 15257947
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
9. Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?
Rodriguez J
Nat Clin Pract Oncol; 2005 Feb; 2(2):74-5. PubMed ID: 16264876
[No Abstract] [Full Text] [Related]
10. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?
Eisenbeis CF; Caligiuri MA; Byrd JC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5810-2. PubMed ID: 14676100
[No Abstract] [Full Text] [Related]
11. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
Williams ME
Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271
[No Abstract] [Full Text] [Related]
12. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
Grillo-López AJ
Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
[TBL] [Abstract][Full Text] [Related]
13. [Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
Mayer J; Navrátil M; Vásová J; Vorlícek J
Vnitr Lek; 2001 Sep; 47 Suppl 1():57-62. PubMed ID: 11693064
[TBL] [Abstract][Full Text] [Related]
14. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
15. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL.
Schmidt HH; Renner H; Linkesch W
Haematologica; 2004 Nov; 89(11):ECR39. PubMed ID: 15533844
[TBL] [Abstract][Full Text] [Related]
16. Primary non-Hodgkin's lymphoma in the esophagus.
Zhu Q; Xu B; Xu K; Li J; Jin XL
J Dig Dis; 2008 Nov; 9(4):241-4. PubMed ID: 18959598
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma.
Shvidel L; Klepfish A; Berrebi A
Am J Hematol; 2001 Jul; 67(3):213-4. PubMed ID: 11391724
[No Abstract] [Full Text] [Related]
19. Rituxan delays disease progression in indolent non-Hodgkin's lymphoma.
Oncology (Williston Park); 2002 Nov; 16(11):1472. PubMed ID: 12469926
[No Abstract] [Full Text] [Related]
20. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]